NCT02698566View on ClinicalTrials.gov

A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 21, 2016

Primary Completion Date

April 5, 2016

Study Completion Date

April 5, 2016

Conditions
Macular Edema
Interventions
DRUG

Ranibizumab

Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.

Trial Locations (4)

28210

Char Eye Ear &Throat Assoc, Charlotte

37421

Southeastern Retina Associates, Chattanooga

38138

Charles Retina Institution, Germantown

42001

Paducah Retinal Center, Paducah

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02698566 - A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS) | Biotech Hunter | Biotech Hunter